C4 Therapeutics, Inc.
CCCCC4 Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted protein degradation therapies for serious diseases, including cancer and rare disorders. Utilizing its proprietary Controlled Covalent Catalysis (C4) platform, the company designs small molecules that selectively bind to and induce the degradation of disease-causing proteins, aiming to create innovative treatments with improved efficacy and safety profiles.
Company News
C4 Therapeutics announced strategic milestones through 2028 for advancing cemsidomide, an investigational IKZF1/3 degrader for multiple myeloma. The company plans to initiate Phase 2 MOMENTUM trial in Q1 2026 and Phase 1b combination trial with elranatamab in Q2 2026, with a recommended Phase 2 dose of 100 µg. Phase 1 data showed 53% overall res...
C4 Therapeutics, a clinical-stage biopharmaceutical company focused on protein degradation science, will participate in the 8th Annual Evercore Healthcare Conference on December 3rd, 2025, presenting a fireside chat with live webcast.
C4 Therapeutics saw a significant stock price increase of over 34% after Stephens analyst Sudan Loganathan upgraded the stock to overweight, citing promising pipeline progress and potential in multiple myeloma drug market.
C4 Therapeutics reported positive data for its multiple myeloma drug candidate cemsidomide, with a 50% overall response rate at the highest dose level. The company is prioritizing the development of cemsidomide and plans to seek partnership opportunities for its BRAF program.
The BRAF inhibitor market is expected to grow significantly due to the increasing number of cancer patients, rise in biomarker testing, and ongoing research and development of next-generation BRAF-targeting therapies.
